Contribution of SARS-CoV-2 Accessory Proteins to Viral Pathogenicity in K18 Human ACE2 Transgenic Mice.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
10 08 2021
Historique:
pubmed: 17 6 2021
medline: 17 8 2021
entrez: 16 6 2021
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the viral pathogen responsible for the current coronavirus disease 2019 (COVID-19) pandemic. As of 19 May 2021, John Hopkins University's COVID-19 tracking platform reported 3.3 million deaths associated with SARS-CoV-2 infection. Currently, the World Health Organization has granted emergency use listing (EUL) to six COVID-19 vaccine candidates. However, much of the pathogenesis observed during SARS-CoV-2 infection remains elusive. To gain insight into the contribution of individual accessory open reading frame (ORF) proteins in SARS-CoV-2 pathogenesis, we used our recently described reverse-genetics system approach to successfully engineer recombinant SARS-CoV-2 (rSARS-CoV-2) constructs; we removed individual viral ORF3a, -6, -7a, -7b, and -8 proteins from them, and we characterized the resulting recombinant viruses

Identifiants

pubmed: 34133899
doi: 10.1128/JVI.00402-21
pmc: PMC8354228
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines, Attenuated 0
Viral Proteins 0
ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0040221

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI161175
Pays : United States
Organisme : NIH HHS
ID : S10 OD026880
Pays : United States

Références

Int J Biol Macromol. 2021 Feb 15;170:820-826
pubmed: 33359807
Infect Genet Evol. 2019 Jul;71:21-30
pubmed: 30844511
Arch Virol Suppl. 2005;(19):157-77
pubmed: 16355872
Science. 2020 Jul 17;369(6501):297-301
pubmed: 32471856
Heliyon. 2021 Feb;7(2):e06155
pubmed: 33553782
Nat Commun. 2020 Nov 30;11(1):6122
pubmed: 33257679
mSystems. 2020 May 5;5(3):
pubmed: 32371472
Mol Cell. 2020 Dec 17;80(6):1055-1066.e6
pubmed: 33188728
Virulence. 2016 Nov 16;7(8):871-881
pubmed: 27248570
J Virol. 2006 Jan;80(2):785-93
pubmed: 16378980
J Virol. 2005 Dec;79(23):14909-22
pubmed: 16282490
Pediatr Res. 2015 Oct;78(4):380-8
pubmed: 26107392
J Virol. 2012 Apr;86(7):3995-4008
pubmed: 22278237
Lancet Infect Dis. 2014 Feb;14(2):140-5
pubmed: 24355866
J Virol. 2008 Oct;82(19):9477-91
pubmed: 18632859
J Virol. 2007 Jan;81(2):718-31
pubmed: 17079322
Emerg Microbes Infect. 2020 Dec;9(1):1418-1428
pubmed: 32529952
Malays J Pathol. 2020 Apr;42(1):3-11
pubmed: 32342926
J Virol. 2017 Mar 29;91(8):
pubmed: 28148787
Nat Genet. 2020 Oct;52(10):991-998
pubmed: 32908258
mBio. 2020 Sep 25;11(5):
pubmed: 32978313
J Virol. 2021 Jan 11;:
pubmed: 33431557
Virology. 2020 Sep;548:39-48
pubmed: 32838945
Epidemiol Infect. 2020 Oct 26;148:e262
pubmed: 33100263
Viruses. 2020 Jun 06;12(6):
pubmed: 32517266
Sci Rep. 2017 Nov 23;7(1):16160
pubmed: 29170504
Nature. 2021 Jun;594(7862):246-252
pubmed: 33845483
J Virol. 2007 Jan;81(2):548-57
pubmed: 17108024
Gac Med Mex. 2020;156(2):132-137
pubmed: 32285862
Sci Rep. 2016 May 17;6:26100
pubmed: 27185466
J Infect Dev Ctries. 2020 Jan 31;14(1):3-17
pubmed: 32088679
Nat Rev Microbiol. 2016 Aug;14(8):523-34
pubmed: 27344959
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
Nat Commun. 2020 Jul 30;11(1):3810
pubmed: 32733001
FASEB J. 2019 Aug;33(8):8865-8877
pubmed: 31034780
Cell Death Discov. 2019 Jun 5;5:101
pubmed: 31231549
mBio. 2020 Jul 21;11(4):
pubmed: 32694143
Cell Mol Immunol. 2020 Aug;17(8):881-883
pubmed: 32555321
Dev Cell. 2021 Feb 22;56(4):427-442.e5
pubmed: 33422265
J Virol. 2010 Jan;84(2):1097-109
pubmed: 19889773
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
J Vis Exp. 2011 Nov 01;(57):e3400
pubmed: 22083261

Auteurs

Jesus A Silvas (JA)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Desarey Morales Vasquez (DM)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Jun-Gyu Park (JG)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Kevin Chiem (K)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Anna Allué-Guardia (A)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Andreu Garcia-Vilanova (A)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Roy Neal Platt (RN)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Lisa Miorin (L)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Thomas Kehrer (T)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Anastasija Cupic (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Ana S Gonzalez-Reiche (AS)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Harm van Bakel (HV)

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Adolfo García-Sastre (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Global Health Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Tim Anderson (T)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Jordi B Torrelles (JB)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Chengjin Ye (C)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Luis Martinez-Sobrido (L)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH